NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG
    DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG
    India

    DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG

    Written by Pratyush Deep Kotoky
    July 09, 2021 | 03:01 am 3 min read
    DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG
    Mankind Pharma will be manufacturing 2-DG at its facilities in Visakhapatnam and Himachal Pradesh.

    Pharmaceutical firm Mankind Pharma on Thursday announced that it has received approval from the Defence Research and Development Organisation (DRDO) to manufacture and market the COVID-19 drug 2-Deoxy-D-Glucose or 2-DG. The drug was developed by Defence Research Development Establishment (DRDE), Gwalior, and clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr. Reddy's Laboratories.

    Aim is to ensure maximum reach of drug: Mankind Pharma

    Mankind Pharma, popular for its brands Manforce and Prega News, said in a statement on Thursday that it will manufacture the anti-COVID-19 drug at its facilities in Visakhapatnam and Himachal Pradesh. The company said, "Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic."

    How effective is the drug against COVID-19?

    2-DG helps in the recovery of hospitalized patients and is recommended for moderate to severe COVID-19 patients under a physician's supervision as an adjunct therapy. It selectively accumulates in virus-infected cells and stops viral synthesis and energy production. The drug also alleviates cells from infection-induced cytopathic effects and cell death. It helps patients recover faster and reduces their dependence on supplemental oxygen.

    Apart from Mankind Pharma, who else is manufacturing the drug?

    Apart from Mankind Pharma, other companies such as Laurus Labs, Bajaj Healthcare have also received approvals to manufacture the drug. Another drugmaker, Shilpa Medicare, has also announced that it had received in-principle approval from DRDO. According to officials, since the drug is a generic molecule and analog of glucose, it can be easily produced and can be made available in plenty.

    How much will it cost?

    The drug comes in powder form in a sachet and can be taken orally by dissolving it in water. Reportedly, the drug will be available in the market at a fixed price of Rs. 990. However, the DRDO will provide the drug for free to state and central governments. Notably, Dr. Reddy's has been producing the drug in limited quantity for hospitals.

    Drug can be only used to treat moderate-severe patients

    2-DG, which was given approval for emergency use on May 1, can only be used to treat moderate to severe COVID-19 patients. While the drug is strictly prohibited to pregnant and lactating women and patients under 18 years, people with uncontrolled diabetes, cardiac problems, ARDS, severe hepatic and renal impairment are also advised to take caution before taking the drug.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Defence Research and Development Organisation (DRDO)
    Drugs Controller General of India
    Coronavirus

    Defence Research and Development Organisation (DRDO)

    COVID-19 drug 2-DG launched: All you need to know Coronavirus
    DRDO's anti-coronavirus drug: Its efficacy, price, and more queries answered India
    DRDO's anti-coronavirus drug cleared for emergency use by DCGI India
    DRDO to set up 500 oxygen plants within three months Rajnath Singh

    Drugs Controller General of India

    Expert panel says no to Covovax's children trials in India Central Drugs Standard Control Organization (CDSCO)
    Zydus applies for approval of its 3-dose, needle-free COVID-19 vaccine Zydus Cadila
    Bharat Biotech submits COVAXIN phase-3 trial data, review meet today COVID-19
    COVID-19: DCGI gives approval for phase-2 clinical trials of Colchicine Health & Wellness

    Coronavirus

    US coronavirus cases rising sharply as Delta variant spreads Joe Biden
    Global COVID-19 deaths hit four million amid rush to vaccinate COVID-19
    Coronavirus: India reports nearly 46K new cases, 800+ deaths Ministry of Health and Family Welfare
    Lowest weekly COVID-19 deaths since October registered globally: WHO World Health Organization
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023